Genentech is a leading biotech company. Our partnership with the hemophilia community began over 30 years ago when we developed the first cloned, virus-free, nonblood-derived version of the factor VIII protein.* Since then, we haven’t stopped working toward our goal of advancing and improving treatment. But this partnership goes far beyond developing medicines. Genentech is committed to advancing all aspects of life with hemophilia A, starting with patient care. We strive to provide Treatment for All who need it, including underserved communities around the globe. We Support the Person through education, resources, and tools designed to help individuals thrive throughout their treatment journey. We Connect the Community through active engagements that help bring these individuals together to learn and grow. Each day, we work alongside the community to improve life with hemophilia A by creating what’s next together. *Genentech outlicensed worldwide production and marketing of factor VIII.